Advanced Research Center Inc

1. Teva Pharmaceuticals USA, Inc. $4,907,966 324 payments
2. ITI, Inc. $4,447,309 1,154 payments
3. AbbVie, Inc. $4,048,867 315 payments
4. Regeneron Pharmaceuticals, Inc. $2,771,611 74 payments
5. Allergan Inc. $2,668,276 251 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $2,387,789 1,094 payments
7. Sage Therapeutics, Inc. $2,110,088 68 payments
8. Pfizer Inc. $818,711 57 payments
9. BioXcel Therapeutics, Inc. $564,797 4 payments
10. Otsuka Pharmaceutical Development & Commercialization, Inc. $424,963 20 payments

1. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $3,874,697 109 payments
2. Iti-007-452 $3,004,815 732 payments
3. Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Nsaid Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $2,274,581 61 payments
4. A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $1,316,551 957 payments
5. A Comparative Study of Sage-217 Plus Sertraline Versus Placebo Plus Sertraline in Adults With Major Depressive Disorder $1,001,947 21 payments
6. Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of A 12-Week Double-Blind, Placebo-Controlled Part (Part A) to Evaluate Efficacy and Safety Followed By A 36-Week Double-Blind Extension Part (Part B) to Document Long-Term Safety Up to Week 48 $965,192 103 payments
7. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia $895,386 28 payments
8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in Theprevention of Relapse in Patients With Schizophrenia $865,853 48 payments
9. Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder $798,959 18 payments
10. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $748,922 38 payments

1. Other $194,618 13 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.